Patents by Inventor Miles B. Brennan
Miles B. Brennan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9719107Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.Type: GrantFiled: October 23, 2015Date of Patent: August 1, 2017Assignee: Isogenis, Inc.Inventors: Miles B. Brennan, Erin K. Spiegel, Uwe D. Staerz, Charles Wall, Janae Wheeler, William J. Maslanik, Xianghua Zhang
-
Publication number: 20160168591Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.Type: ApplicationFiled: October 23, 2015Publication date: June 16, 2016Inventors: Miles B. Brennan, Erin K. Spiegel, Uwe D. Staerz, Charles Wall, Janae Wheeler, William J. Maslanik, Xianghua Zhang
-
Patent number: 9169493Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.Type: GrantFiled: September 24, 2014Date of Patent: October 27, 2015Assignee: Isogenis, Inc.Inventors: Miles B. Brennan, Erin K. Spiegel, Uwe D. Staerz, Charles Wall, Janae Wheeler, William J. Maslanik, Xianghua Zhang
-
Publication number: 20150093831Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.Type: ApplicationFiled: September 24, 2014Publication date: April 2, 2015Inventors: Miles B. Brennan, Erin K. Spiegel, Uwe D. Staerz, Charles Wall, Janae Wheeler, William J. Maslanik, Xianghua Zhang
-
Patent number: 8871515Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.Type: GrantFiled: September 17, 2009Date of Patent: October 28, 2014Assignee: Isogenis, Inc.Inventors: Miles B. Brennan, Erin K. Spiegel, Uwe D. Staerz, Charles Wall, Janae Wheeler, William J. Maslanik, Xianghua Zhang
-
Patent number: 7919577Abstract: ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.Type: GrantFiled: October 27, 2005Date of Patent: April 5, 2011Assignees: Colorado Seminary, Oklahoma Medical Research Foundation, The University of Florida Research Foundation, Inc.Inventors: Miles B. Brennan, Jessica L Costa, Robert M. Dores, Ute H. Hochgeschwender, Carrie Haskell-Luevano
-
Publication number: 20100260681Abstract: ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.Type: ApplicationFiled: May 11, 2010Publication date: October 14, 2010Inventors: MILES B. BRENNAN, JESSICA L. COSTA, ROBERT M. DORES, UTE H. HOCHGESCHWENDER, CARRIE HASKELL-LUEVANO
-
Publication number: 20100120155Abstract: The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder.Type: ApplicationFiled: September 17, 2009Publication date: May 13, 2010Inventors: Miles B. Brennan, Erin K. Spiegel, Uwe D. Staerz, Charles Wall, Janae Wheeler, William J. Maslanik, Xianghua Zhang
-
Patent number: 7655622Abstract: Methods for regulating body weight and/or regulating weight gain are provided herein. The methods are useful, for instance, for treating or preventing obesity. Specifically, methods of administering varying levels of various alpha melanocyte stimulating hormone (?-MSH) analog compounds to an animal are provided for reducing body weight and/or reducing the rate of body weight gain.Type: GrantFiled: January 6, 2004Date of Patent: February 2, 2010Assignees: Eleanor Roosevelt Institute, Oklahoma Medical Research FoundationInventors: Miles B. Brennan, Ute Hochgeschwender
-
Publication number: 20080207518Abstract: ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.Type: ApplicationFiled: October 27, 2005Publication date: August 28, 2008Inventors: Miles B. Brennan, Jessica L. Costa, Robert M. Dores, Ute H. Hochgeschwender, Carrie Haskell-Luevano
-
Patent number: 7264314Abstract: ACTH analog compounds of the present invention include compounds comprising an ACTH peptide sequence with one or more structural modifications that can have one or more of the following preferred ACTH analog biological functions: (1) reduction of corticosteroid secretion by adrenal membrane in the presence of the ACTH analog compared to unmodified ACTH, (2) reduction of corticosteroid secretion by adrenal membrane in the presence of endogenous ACTH and (3) increased MC-2R binding affinity with reduced activation of the MC-2R receptor compared to unmodified ACTH binding to the MC-2R melanocortin. The ACTH analog compounds of the present invention are therefore useful for treatment or prevention of diseases and disorders related to ACTH, ACTH receptors or corticosteroid secretion, such as premature labor and Cushing's Disease.Type: GrantFiled: October 27, 2005Date of Patent: September 4, 2007Inventors: Miles B. Brennan, Jessica Costa, Robert M. Dores, Ute H. Hochgeschwender, Carrie Haskell-Luevano
-
Publication number: 20040175740Abstract: Disclosed is a method to identify compounds useful for reducing insulin resistance in a patient, and particularly a patient that has insulin resistance associated with obesity and/or type II diabetes. Also disclosed is a method of reducing insulin resistance in a patient by administering a compound identified using the method of the invention, and particularly, by administering an antagonist of melanocortin stimulating hormone (MSH) biological activity.Type: ApplicationFiled: January 23, 2004Publication date: September 9, 2004Applicants: Eleanor Roosevelt Institute, Olkahoma Medical Research FoundationInventors: Miles B. Brennan, Ute Bochgeschwender
-
Patent number: 6716810Abstract: Described are methods and compositions for regulating body weight and/or regulating the rate of weight gain or loss, and particularly, for treating or preventing obesity. Specifically, methods of administering varying levels of circulating proopiomelanocortin peptides or analogs thereof to an animal, alone or in combination with leptin or other body weight regulating agents are disclosed. Methods and compositions for treating a variety of disorders associated with or caused by undesirable body weight are also described.Type: GrantFiled: December 9, 1999Date of Patent: April 6, 2004Assignees: Eleanor Roosevelt Institute, Oklahoma Medical Research FoundationInventors: Miles B. Brennan, Ute Hochgeschwender
-
Patent number: 6689938Abstract: Disclosed is a method to identify compounds useful for reducing insulin resistance in a patient, and particularly a patient that has insulin resistance associated with obesity and/or type II diabetes. Also disclosed is a method of reducing insulin resistance in a patient by administering a compound identified using the method of the invention, and particularly, by administering an antagonist of melanocortin stimulating hormone (MSH) biological activity.Type: GrantFiled: September 13, 2001Date of Patent: February 10, 2004Assignee: Oklajoma Medical Research FoundationInventors: Miles B. Brennan, Ute Hochgeschwender
-
Patent number: 6603058Abstract: Described is a genetically modified non-human animal model for studying the peripheral and central pathways of energy homeostasis. Also disclosed are methods of identifying compounds for regulating such pathways and a Pomc mutant mouse.Type: GrantFiled: August 12, 1999Date of Patent: August 5, 2003Assignee: Oklahoma Medical Research FoundationInventors: Miles B. Brennan, Ute Hochgeschwender
-
METHODS FOR IDENTIFYING COMPOUNDS USEFUL FOR THE REGULATION OF BODY WEIGHT AND ASSOCIATED CONDITIONS
Publication number: 20030144174Abstract: Described are methods for identifying compounds useful for regulation of body weight and associated conditions. In particular, methods are disclosed for identification of compounds that preferentially bind to and/or activate peripheral melanocortin receptors and which minimize binding and/or activation of central melanocortin receptors.Type: ApplicationFiled: December 9, 1999Publication date: July 31, 2003Inventors: MILES B. BRENNAN, UTE HOCHGESCHWENDER -
Publication number: 20020099014Abstract: Disclosed is a method to identify compounds useful for reducing insulin resistance in a patient, and particularly a patient that has insulin resistance associated with obesity and/or type II diabetes. Also disclosed is a method of reducing insulin resistance in a patient by administering a compound identified using the method of the invention, and particularly, by administering an antagonist of melanocortin stimulating hormone (MSH) biological activity.Type: ApplicationFiled: September 13, 2001Publication date: July 25, 2002Inventors: Miles B. Brennan, Ute Hochgeschwender
-
Publication number: 20020092034Abstract: Disclosed is a genetically modified non-human animal that is a model for defective folate transport. Specifically the non-human animal comprises a genetic modification that results in decreased or absent expression and/or biological activity of the endogenous reduced folate carrier. The animal can be further modified by introduction into the genome of a nucleic acid molecule encoding the human reduced folate carrier. Such an animal can be used in methods to identify compounds useful for treating a variety of conditions associated with defective folate transport, or for the identification of anti-folate compounds useful for treating cancer. The animal can also be used to study the biochemical and molecular events associated with folate transport. Compounds identified using such a model are valuable for therapeutic treatments.Type: ApplicationFiled: September 24, 2001Publication date: July 11, 2002Inventors: David Patterson, Miles B. Brennan, Ute Hochgeschwender, Wayne F. Flintoff, Heather Sadlish, T. Michael Underhill, Frederick M.R. Williams